BridgeMD
Tests treatment safety and results for Sudden Sensorineural Hearing Loss
Official title Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss
ClinicalTrials.gov ID: NCT06968507
What this study is testing
What is Methylprednisolone (drug)?
Methylprednisolone (drug) is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for sudden sensorineural hearing loss.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn which one works to treat better in patients with sudden sensorineural hearing loss, oral or intratympanic corticosteroid treatment. The main question it aims to answer is: Which corticosteroid treatment is more effective in patients with sudden sensorineural hearing loss, oral or intratympanic?
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- 18 years of age and older
- Unilateral sudden sensorineural hearing loss that developed within 72 hours and has lasted for 14 days or less
- Affected side PTA (500-100-2000-4000hz) should be over 50dB
- Affected side should be at least 30dB lower than healthy side in 3 frequencies
- Hearing should be symmetrical according to patient's statement before sensorineural hearing loss
You likely can't join if
- Having a history of hearing-related surgery other than a ventilation tube
- Having a history of previous hearing loss, fluctuating hearing or Meniere's disease, chronic inflammatory or suppurative ear disease or...
- Being under 18 or over 80
- Having a history of physical-barotrauma
- Presence of structural or retrocochlear pathology in the examination and imaging that would explain the unilateral hearing loss
- Patients diagnosed with tuberculosis or receiving prophylactic tuberculosis treatment, diabetes mellitus, rheumatological patients, those with...
See the full eligibility criteria
- 18 years of age and older
- Unilateral sudden sensorineural hearing loss that developed within 72 hours and has lasted for 14 days or less
- Affected side PTA (500-100-2000-4000hz) should be over 50dB
- Affected side should be at least 30dB lower than healthy side in 3 frequencies
- Hearing should be symmetrical according to patient's statement before sensorineural hearing loss
- If used, steroid use should be less than 10 days
- Cerebellar and vestibular examination should be normal
- Having a history of hearing-related surgery other than a ventilation tube
- Having a history of previous hearing loss, fluctuating hearing or Meniere's disease, chronic inflammatory or suppurative ear disease or cholesteatoma, otosclerosis
- Being under 18 or over 80
- Having a history of physical-barotrauma
- Presence of structural or retrocochlear pathology in the examination and imaging that would explain the unilateral hearing loss
- Patients diagnosed with tuberculosis or receiving prophylactic tuberculosis treatment, diabetes mellitus, rheumatological patients, those with atherosclerotic disease, serious psychiatric patients, those receiving...
The study team makes the final eligibility decision.
Where it's taking place
- Istanbul, Kartal, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Istanbul, Kartal, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.